Probus Surgery Limited 07450536 false 2025-04-01 2026-03-31 2026-03-31 The principal activity of the company is that of a surgical centre providing specialist day case surgery. Digita Accounts Production Advanced 6.30.9574.0 true false false false 07450536 2025-04-01 2026-03-31 07450536 2026-03-31 07450536 bus:OrdinaryShareClass1 2026-03-31 07450536 core:RetainedEarningsAccumulatedLosses 2026-03-31 07450536 core:ShareCapital 2026-03-31 07450536 core:CurrentFinancialInstruments 2026-03-31 07450536 core:CurrentFinancialInstruments core:WithinOneYear 2026-03-31 07450536 core:FurnitureFittings 2026-03-31 07450536 core:OfficeEquipment 2026-03-31 07450536 core:PlantMachinery 2026-03-31 07450536 bus:SmallEntities 2025-04-01 2026-03-31 07450536 bus:AuditExemptWithAccountantsReport 2025-04-01 2026-03-31 07450536 bus:FilletedAccounts 2025-04-01 2026-03-31 07450536 bus:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 07450536 bus:RegisteredOffice 2025-04-01 2026-03-31 07450536 bus:Director1 2025-04-01 2026-03-31 07450536 bus:Director2 2025-04-01 2026-03-31 07450536 bus:Director3 2025-04-01 2026-03-31 07450536 bus:Director4 2025-04-01 2026-03-31 07450536 bus:Director5 2025-04-01 2026-03-31 07450536 bus:OrdinaryShareClass1 2025-04-01 2026-03-31 07450536 bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 07450536 core:ComputerEquipment 2025-04-01 2026-03-31 07450536 core:FurnitureFittings 2025-04-01 2026-03-31 07450536 core:FurnitureFittingsToolsEquipment 2025-04-01 2026-03-31 07450536 core:OfficeEquipment 2025-04-01 2026-03-31 07450536 core:PlantMachinery 2025-04-01 2026-03-31 07450536 core:Subsidiary1 2025-04-01 2026-03-31 07450536 core:Subsidiary1 1 2025-04-01 2026-03-31 07450536 core:Subsidiary1 countries:England 2025-04-01 2026-03-31 07450536 core:Subsidiary2 2025-04-01 2026-03-31 07450536 core:Subsidiary2 1 2025-04-01 2026-03-31 07450536 core:Subsidiary2 countries:England 2025-04-01 2026-03-31 07450536 1 2025-04-01 2026-03-31 07450536 countries:AllCountries 2025-04-01 2026-03-31 07450536 2025-03-31 07450536 core:FurnitureFittings 2025-03-31 07450536 core:OfficeEquipment 2025-03-31 07450536 core:PlantMachinery 2025-03-31 07450536 2024-04-01 2025-03-31 07450536 2025-03-31 07450536 bus:OrdinaryShareClass1 2025-03-31 07450536 core:RetainedEarningsAccumulatedLosses 2025-03-31 07450536 core:ShareCapital 2025-03-31 07450536 core:CurrentFinancialInstruments 2025-03-31 07450536 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 07450536 core:FurnitureFittings 2025-03-31 07450536 core:OfficeEquipment 2025-03-31 07450536 core:PlantMachinery 2025-03-31 07450536 core:Subsidiary1 1 2024-04-01 2025-03-31 07450536 core:Subsidiary2 1 2024-04-01 2025-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 07450536

Probus Surgery Limited
Unaudited Filleted Financial Statements
for the Year Ended 31 March 2026

Probus Surgery Limited

Contents

Company Information | 1
Balance Sheet | 2 to 3
Notes to the Unaudited Financial Statements | 4 to 9

Probus Surgery Limited

Company Information

Directors | Dr G Lin Sin Cho Dr R Murthy Dr K Smithson Dr G E Moon Mr J S Casey

Registered office | The Surgery Tregony Road Probus Cornwall TR2 4JZ

Probus Surgery Limited

(Registration number: 07450536)
Balance Sheet as at 31 March 2026

| Note | 2026 £ | 2025 £
Fixed assets |  |  |
Tangible assets | 4 | 169,918 | 171,184
Investments | 5 | 200 | 200
|  | 170,118 | 171,384
Current assets |  |  |
Stocks |  | 11,842 | 11,842
Debtors | 6 | 431,712 | 409,754
Cash at bank and in hand |  | 905,886 | 1,051,563
|  | 1,349,440 | 1,473,159
Creditors: Amounts falling due within one year | 7 | (594,844) | (541,192)
Net current assets |  | 754,596 | 931,967
Total assets less current liabilities |  | 924,714 | 1,103,351
Provisions for liabilities |  | (41,737) | (41,891)
Net assets |  | 882,977 | 1,061,460
Capital and reserves |  |  |
Called up share capital | 8 | 95 | 95
Retained earnings |  | 882,882 | 1,061,365
Shareholders' funds |  | 882,977 | 1,061,460

Probus Surgery Limited

(Registration number: 07450536)
Balance Sheet as at 31 March 2026

For the financial year ending 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 19 July 2026 and signed on its behalf by:

......................................... Dr G Lin Sin Cho Director

Probus Surgery Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026

1 | General information

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is:
The Surgery
Tregony Road
Probus
Cornwall
TR2 4JZ

These financial statements were authorised for issue by the Board on 19 July 2026.

2 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Disclosure of long or short period

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Probus Surgery Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026

Tax

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.
Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.
Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class | Depreciation method and rate
Plant and machinery | 20% reducing balance
Fixtures and fittings | 20% reducing balance
Computer equipment | 33% reducing balance

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.
Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Probus Surgery Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

3 | Staff numbers

The average number of persons employed by the company (including directors) during the year, was 41 (2025 - 42).

Probus Surgery Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026

4 | Tangible assets

| Fixtures and fittings £ | Plant and machinery £ | Office equipment £ | Total £
Cost or valuation
At 1 April 2025 | 60,842 | 406,300 | 146,093 | 613,235
Additions | 115 | 25,407 | 24,339 | 49,861
At 31 March 2026 | 60,957 | 431,707 | 170,432 | 663,096
Depreciation
At 1 April 2025 | 31,821 | 292,994 | 117,236 | 442,051
Charge for the year | 5,827 | 27,746 | 17,554 | 51,127
At 31 March 2026 | 37,648 | 320,740 | 134,790 | 493,178
Carrying amount
At 31 March 2026 | 23,309 | 110,967 | 35,642 | 169,918
At 31 March 2025 | 29,021 | 113,306 | 28,857 | 171,184

5 | Investments

| 2026 £ | 2025 £
Investments in subsidiaries | 200 | 200

Details of undertakings

Details of the investments (including principal place of business of unincorporated entities) in which the company holds 20% or more of the nominal value of any class of share capital are as follows:

Probus Surgery Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026

Undertaking | Registered office | Holding | Proportion of voting rights and shares held
|  |  | 2026 | 2025
Subsidiary undertakings
Cornwall Medical Group Limited | The Surgery Tregony Road Probus Truro Cornwall England | 100 Ordinary shares | 100% | 100%
Probus Medicines Limited | The Surgery Tregony Road Probus Truro Cornwall England | 100 Ordinary shares | 100% | 100%

Subsidiary undertakings
Cornwall Medical Group Limited The principal activity of Cornwall Medical Group Limited is the provision of specialist medical practice activities.
Probus Medicines Limited The principal activity of Probus Medicines Limited is operating as a dispensing chemist.

6 | Debtors

Current | Note | 2026 £ | 2025 £
Trade debtors |  | 243,160 | 224,173
Amounts owed by related parties |  | 178,114 | 168,962
Prepayments |  | 9,893 | 7,556
Other debtors |  | 545 | 9,063
|  | 431,712 | 409,754

Probus Surgery Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026

7 | Creditors

Creditors: amounts falling due within one year

| 2026 £ | 2025 £
Due within one year |  |
Trade creditors | 226,297 | 224,574
Taxation and social security | 272,785 | 225,588
Accruals and deferred income | 18,550 | 3,499
Other creditors | 77,212 | 87,531
| 594,844 | 541,192

8 | Share capital

Allotted, called up and fully paid shares

| 2026 | 2025
| No. | £ | No. | £
Ordinary shares of £0.01 each | 9,500 | 95 | 9,500 | 95

9 | Financial commitments, guarantees and contingencies

Amounts not provided for in the balance sheet

The total amount of financial commitments not included in the balance sheet is £555,216 (2025 - £773,404).